BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:24 PM
Apr 03, 2007
 |  BC Extra  |  Clinical News

Cell Genesys jumps on prostate vaccine data

CEGE gained $1.39 (32%) to $5.70 on Tuesday after it reported that updated Phase II data from 22 patients receiving the highest dose of GVAX immunotherapy for prostate cancer showed a median...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >